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The Role of Telomerase Protein TERT in Alzheimer’s Disease
and in Tau-Related Pathology In Vitro
Alison Spilsbury,1,2 Satomi Miwa,1,2 Johannes Attems,1,3 and XGabriele Saretzki1,2
1Newcastle University Institute for Ageing, Campus for Ageing and Vitality, 2Institute for Cell and Molecular Bioscience, and 3Institute of Neuroscience,
Newcastle University, Newcastle upon Tyne, NE4 5PL, UK
The telomerase reverse transcriptaseproteinTERThas recently beendemonstrated tohave a variety of functionsboth in vitro and in vivo,
which are distinct from its canonical role in telomere extension. In different cellular systems, TERT protein has been shown to be
protective through its interaction with mitochondria. TERT has previously been found in rodent neurons, and we hypothesize that it
might have a protective function in adult human brain. Here, we investigated the expression of TERT at different stages of Alzheimer’s
disease pathology (Braak Stages I-VI) in situ and the ability of TERT to protect against oxidative damage in an in vitro model of tau
pathology.Ourdata reveal that TERT is expressed in vitro inmouseneurons andmicroglia, and in vivo in the cytoplasmofmature human
hippocampal neurons and activated microglia, but is absent from astrocytes. Intriguingly, hippocampal neurons expressing TERT did
not contain hyperphosphorylated tau. Vice versa, neurons that expressed high levels of pathological tau did not appear to express TERT
protein. TERT protein colocalized with mitochondria in the hippocampus of Alzheimer’s disease brains (Braak Stage VI), as well as in
cultured neurons under conditions of oxidative stress. Our in vitro data suggest that the absence of TERT increases ROS generation and
oxidative damage in neurons induced by pathological tau. Together, our findings suggest that TERT protein persists in neurons of the
adult human brain, where it may have a protective role against tau pathology.
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Introduction
Alzheimer’s disease (AD) is a progressive neurodegenerative con-
dition affecting 35 million individuals worldwide (Selkoe,
2012). Accumulation of both hyperphosphorylated (Alonso et
al., 1996) and truncated (Basurto-Islas et al., 2008) microtubule-
associated tau protein into neurofibrillary tangles (NFTs) and
neuropil threads (NTs) is a pathological hallmark of AD (Alonso
et al., 1996). These tau forms cause disrupted axonal trafficking of
mitochondria (Stamer et al., 2002; Dubey et al., 2008; Reddy,
2011) and impair respiration (Rhein et al., 2009), eventually lead-
ing to cell death (Yang et al., 2003). The gray matter is dense with
mitochondria, which provide sufficient energy to maintain syn-
aptic activity (Wong-Riley, 1989; Attwell and Laughlin, 2001).
However, mitochondrial function declines with age and can be
impaired in neurodegenerative diseases (Shigenaga et al., 1994;
Beal, 2005; Eckert et al., 2010). Dysfunctional mitochondria con-
tribute to oxidative stress, through generation of ROS, which
have been linked to brain aging and neurodegeneration (Barn-
ham et al., 2004; Lin and Beal, 2006; Chou et al., 2011).
Telomerase is a reverse transcriptase best known for its telo-
mere maintenance function in dividing cells. This requires two
subunits: the enzyme TERT (telomerase reverse transcriptase)
and the RNA component TERC (telomerase RNA component).
However, an extranuclear localization of TERThas been reported
(Haendeler et al., 2003, 2009; Ahmed et al., 2008; Eitan et al.,
2012a). In rodents, TERT expression is maintained into adult-
hood (Klapper et al., 2001; Lee et al., 2010); and although telom-
erase activity is confined to areas containing stem cells (Caporaso
et al., 2003), nontelomeric functions of the TERT protein have
been shown in adult neurons (Kang et al., 2004; Iannilli et al.,
2013). However, there is little information regarding TERT ex-
pression in human brain tissue, aside from its strong upregula-
tion in brain tumors (Shay and Bacchetti, 1997; Falchetti et al.,
2002; Koelsche et al., 2013).
Prosurvival effects of telomerase have been demonstrated in
rodent neurons following various insults, such as ischemia, am-
yloid peptides, and both glutamate and NMDA-induced neuro-
toxicity (Fu et al., 2000; Zhu et al., 2000; Klapper et al., 2001; Lu et
al., 2001; Kang et al., 2004; Lee et al., 2008). Several in vitro studies
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have demonstrated the ability of TERT to shuttle from the nu-
cleus to mitochondria upon oxidative stress, where it decreases
levels of ROS, DNA damage, and apoptosis, and improves mito-
chondrial membrane potential, respiration, and complex I activ-
ity (Ahmed et al., 2008; Haendeler et al., 2009; Singhapol et al.,
2013).
In this study, we investigated the ability of TERT to protect
against tau pathology. We demonstrate that TERT protein is ex-
pressed in adult human hippocampal neurons. We show that
TERT localizes to mitochondria upon oxidative stress in culti-
vated neurons and in the hippocampal neurons of AD brains.
Additionally, there is a mutual exclusion of TERT and NFT/NT.
Neurons lacking TERT display an increased production of oxi-
dative species and an increase in cellular oxidative damage in
response to tau. Together, our results suggest that TERT protects
hippocampal neurons against oxidative stress induced by patho-
logical tau.
Materials andMethods
All chemicals were from Sigma, and all culture media from Invitrogen
unless otherwise stated.
Human hippocampal tissue. Our study used 24 postmortem brains: 6
age-matched controls without tau pathology, 12 with Braak stages rang-
ing from I to III and 6 with AD (Braak Stage VI) (Braak and Braak, 1991;
Braak et al., 2006) (Table 1). Brain tissue was collected by the Newcastle
Brain Tissue Resource at Newcastle University, United Kingdom, after
relevant informed consent from donors and in accordance with New-
castle University ethics board and ethical approval awarded by the Joint
Ethics Committee of Newcastle and North Tyneside Health Authority
(reference 08/H0906/136). All brains were assessed neuropathologically
according to published criteria (Mirra et al., 1991; Thal et al., 2002; Braak
et al., 2006; Montine et al., 2012) and were free of non-AD pathology in
the hippocampus (e.g., Lewy body pathology, TDP-43 inclusions, hip-
pocampal sclerosis).
Mice. TERT knock-out mice (TERT/) (Chiang et al., 2004) were
obtained from The Jackson Laboratory and had the genotype B6.129S-
Tert, tm1Yjc/J. Heterozygous mice were bred to obtain wild-type and
first generation (G1) homozygous knock-out mice. Ethical approval was
granted by the Local Research Ethics Committee, Newcastle University,
UK. The work was licensed by the UK Home Office (PPL 60/3864) and
complied with the guiding principles for the care and use of laboratory
animals in the United Kingdom. The housing and use of mice were
according to local guidelines and governed by theUKAnimals (Scientific
Procedures) Act 1986. Animals were housed in conventional clean facil-
ity in North Kent Plastic M2 cages in the same room and provided with
sawdust, paper bedding, and had ad libitum access towater and food. The
diet used was standard rodent chow (CRM (P), Special Diets Services).
Mice were housed at 20 2°C under a 12 h light/12 h dark photoperiod.
The dams and embryos were killed by a schedule 1 method.
Lentiviral constructs. Full-length human T40 tau in pET29b() was
obtained from Addgene (Peter Klein (Hedgepeth et al., 1997), Addgene
plasmid 16316, Cambridge), and the tau gene was cut from the vector
using EcoRI and XbaI. Following restriction digest, the gene was trun-
cated at aa151–391 by PCR with primers designed by Zilkova et al.
(2011). Truncated tau was ligated into pENTR2B (Invitrogen). Mutated
P301L tau (2N4R) in pENTR/SD/TOPO was kindly provided by Prof.
Juergen Goetz (University of Queensland, Brisbane, Australia). The
truncated tau and P301L tau genes were transferred to pLenti6/V5-DEST
vectors (Invitrogen), using LR Clonase II, according to the manufac-
turer’s guidelines (Invitrogen). Gene inserts were sequenced (GATC
Biotech) to verify correct orientation and absence of any nucleotide
mutations.
Immunofluorescent staining of human hippocampal tissue. Immunoflu-
orescent staining of human hippocampal sections was conducted. Sec-
tions (10M) were deparaffinized in Histo-Clear (National Diagnostics)
and rehydrated in decreasing concentrations of methanol. Antigen re-
trieval was performed in 0.01 M citrate buffer with 0.005% Tween 20 by
microwaving at full power (800 W) for 4 min, and at 40% power for a
further 10 min. Sections were treated with 70% formic acid for 10 min,
followed by Sudan black (0.5% w/v in 70% ethanol) for a further 30 min
to reduce lipofuscin autofluorescence. Sections were blocked in PBS con-
taining 10% normal goat serum (NGS) and 0.1% BSA at room temper-
ature for 60 min. Sections were incubated in a humidified chamber
overnight at 4°Cwith primary antibodies (Table 2) in PBS containing 2%
NGS and 0.1% BSA. Negative controls where the primary antibody was
omitted were included in all experiments (see Fig. 1A, right, top row).
Appropriate AlexaFluor-conjugated secondary antibodies (Invitrogen)
Table 1. Age, gender, Braak stages, PMD, and use of brains in the studya
Case no. Thal A phase Braak stage CERAD AD neuropathologic change Age (yr) Gender PMD (h) Analysis
1 0 0  No 68 M 54 WB/IF/ELISA
2 1 0  Low 78 F 34 WB/IF/ELISA
3 0 0  No 73 M 25 WB/IF/ELISA
4 0 0  No 63 M 30 ELISA
5 1 0  Low 75 M 20 ELISA
6 0 0  No 59 F 19 ELISA
7 1 1  Low 73 F 16 WB/IF/ELISA
8 1 1  Low 72 M 17 ELISA
9 1 2 A Low 83 F 19 WB/IF/ELISA
10 1 2  Low 74 F 45 WB/IF/ELISA
11 2 2 A Low 87 M 8 ELISA
12 1 2  Low 78 F 23 ELISA
13 0 3  No 88 F 22 WB/IF/ELISA
14 2 3  Low 89 F 34 WB/IF/ELISA
15 0 3  No 81 M 43 WB/IF/ELISA
16 2 3 A Low 84 F 8 ELISA
17 3 3 A Intermediate 91 M 12 ELISA
18 4 3 C Intermediate 79 M 13 ELISA
19 4 6 C High 83 F 12 WB/IF/ELISA
20 5 6 C High 86 F 5 WB/IF/ELISA
21 5 6 C High 76 F 37 WB/IF/ELISA
22 4 6 C High 72 F 27 ELISA
23 5 6 B High 77 F 30 ELISA
24 4 6 C High 59 M 44 ELISA
aPMD, Postmortem delay; WB, Western blotting; IF, immunofluorescence.
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were applied for 60 min. When used, NeuroTrace (1:150, Invitrogen) in
PBS was applied for 20 min at room temperature before counterstaining
withDAPI. Sections were stainedwithDAPI (CystainUVPloidy, Partec)
for 15 min and coverslips (Agar Scientific, VWR) were mounted using
Vectashield anti-fade mounting solution (Vector Laboratories). Images
were acquired using fluorescence microscopy (Leica DM5500B, Leica
Microsystems; Axio Observer.Z1, Zeiss) or confocal microscopy (Zeiss
Observer Z1, Quant EM 512SC camera, with Yokogawa CSU-X1
spinning-disk). Individual neurons were outlined and fluorescence in-
tensity measured and taken as average pixel intensity over the total area.
The background value was then subtracted. To measure colocalization
between TERT andmitochondria, images were analyzed using the JaCoP
plug-in for ImageJ. Briefly, images (z-stacks) were thresholded and ana-
lyzed for spatial colocalization using the Pearson’s correlation coefficient
(0, no colocalization; 1, total colocalization; x-, y-, z-block sizes were
2px). Subsequently, Costes’ method was used to create randomized im-
ages of the TERT channel (50 randomization rounds per z-stack slice, bin
width of 0.001), which were compared with the mitochondrial channel,
from which a second Pearson’s correlation coefficient was calculated.
This value was then compared with the original colocalization calcula-
tion. Resulting p values95% indicated that colocalization in the origi-
nal image was not through random chance. Statistical analysis was
performed using one-way ANOVA with Tukey’s post hoc test.
Western blotting. Total protein was extracted from frozen human hip-
pocampal tissue or primary neurons in a lysis buffer containing 50 mM
Tris base, pH 7.5, 150 mM NaCl, 1% Triton X-100, and Halt Protease
Inhibitor Cocktail 100 (Thermo Fisher). Denatured samples (100 g/
lane) were run on 8% SDS-polyacrylamide gels alongside molecular
weight markers (MW 10,000–250,000; PageRuler Plus, Thermo Fisher)
and transferred to nitrocellulose membranes by wet electroblotting.
Membranes were blocked in TTBS containing 5% (w/v) skimmed milk
powder (Marvel) for 1 h at room temperature and incubated with pri-
mary antibodies (Table 2) overnight at 4°C in TTBS/milk. Blots were
incubated with HRP-conjugated secondary antibodies (1:1000; Abcam)
in TTBS/milk for 1 h. Finally, the blots were exposed to ECL Plus/Prime
reagent (GEHealthcare) and placed in an ImageQuant LAS-4000 chemi-
luminescent detector (GE Healthcare). Relative band intensities were
obtained by densitometric analysis of images using ImageJ. Background
signal was subtracted from each band; the values were normalized to the
loading control III-tubulin and expressed as mean  SEM. Data were
analyzed using one-way ANOVA.
Mitochondrial subfractionation. Mitochondria were isolated from
mouse liver, as described previously (Miwa et al., 2014). Briefly, mouse
liver was chopped and rinsed in ice-cold isolation medium (250 mM
sucrose, 5 mM Tris base, and 2 mM EGTA, pH 7.4, at 4°C) and was
homogenized by a glass homogenizer (Wheaton 15 ml Dounce tissue
grinder) using six strokeswith a loose-fit pestle and centrifuged at 1050
g for 3 min. The supernatant was centrifuged at 11,630  g for 10 min,
and the pellet was washed two more times in isolation medium. The
resultant pellet was resuspended in 0.5 ml of isolation medium (crude
mitochondria) followed by purification by Percoll density centrifugation
using a stepwise density gradient of 2 ml 80%, 6 ml 52%, and 6 ml 26%
Percoll in isolationmedium, at 41,100 g for 45min. Themitochondria
were collected from the 26%/52% interface and washed twice with isola-
tion medium at 11,600  g to obtain the purified mitochondria. An
aliquot of each liver homogenate and of pure mitochondria was snap
frozen in liquid N2.
To obtain mitoplasts, 1 ml of 10 mM Tris/HCl at pH 7.4 was added to
1 mg of pure mitochondria and the sample divided into two aliquots of
500l each. To obtain proteinase K-shavedmitoplasts, proteinase K (2.7
g) was added to one aliquot of mitoplasts at a final concentration of 5.4
ng/l and incubated for 30 min on ice. The reaction was stopped by
adding 5 mM PMSF. An equal volume of 2 STE buffer was added to
both aliquots, and they were centrifuged at 12, 000 g for 10min at 4°C.
The pellets were resuspended in 60 l STE. The aliquot of nonshaved
mitoplasts was snap frozen in liquid N2. The shaved mitoplasts were
divided into two aliquots of 30 l: one was snap frozen (mitoplast 
Proteinase K) and to the other 970 l of STE was added and the sample
centrifuged at 12,000 g for 10 min at 4°C. To the pellet, 2.7 ml of 100
mM NaCO3 was added and incubated for 30 min on ice. The sample was
centrifuged at 100,000 g for 15min at 4°C to obtain a pellet containing
the inner membrane fraction, which was resuspended in 30 l STE and
snap frozen in liquid N2.
TERT ELISA. TERT ELISA (GenWay) was performed according to the
manufacturer’s guidelines. Frozen hippocampal tissue lysates were pre-
pared using the identical method as for Western blotting. TERT ELISA
(GenWay) was performed using 100g of total protein per sample, each
run in duplicate. Plates were read in a microplate reader at a wavelength
of 450 nm (FLUOstar Omega, BMGLabtech). Standards of recombinant
TERT protein at concentrations between 50 and 3.125 g were run in
duplicate, from which a linear regression curve was drawn with an r 2
value of 0.996. From this graph, the amount of TERT in each sample was
calculated. Data were analyzed using one-way ANOVA.
Telomerase activity measurements using TRAP ELISA. Measurement of
telomerase activity in cultivated neurons was performed using the Telo-
TAGGG Telomerase PCR ELISA (Roche), according to the manufactur-
er’s guidelines. Total protein was extracted from neurons at 3–14 DIV
using CHAPS buffer, protein quantified using Bradford reagent, and 500
ng of protein was used for each sample. PCR was run at 30 cycles and the
ELISA measured at 450 nm on a plate reader (FLUOstar Omega, BMG
Labtech). Values of0.2 are considered negative according to the man-
ufacturer’s guidelines.
Primary astrocyte and neuronal culture. For the generation of embryos,
wild-type mice and first generation TERT / mice were timed mated.
Primary cultures were prepared from 16-day-old embryos of either sex,
using methods described previously (Spilsbury et al., 2012). Astrocytes
were cultivated as described previously (Spilsbury et al., 2012). Neuronal
cultureswere seeded at a density of 1 106 cells/ml on culture dishes that
had been coated previously with 15 g/ml poly-L-ornithine overnight,
subsequently washed, and then coated with 5 g/ml laminin. Neurons
weremaintained inNeurobasal medium supplemented with 2%B27, 0.5
mMmL-glutamine, and 100 U/ml penicillin/100g/ml streptomycin (all
from Invitrogen). After 4–5 DIV, 5 M arabinofuranosyl cytidine was
added to the culturemedia to limit proliferation of glial cells. All primary
cells were cultured at 37°C in a humidified atmosphere of 5% CO2 and
3% O2. Neurons were transduced at 8 DIV and analyzed after 11 DIV,
when the majority of cells were neuronal, as verified by III-tubulin and
GFAP immunofluorescence and had lost telomerase activity.
Lentiviral transductions. Lentiviral transductions were performed ac-
cording to the manufacturer’s guidelines (Invitrogen), with slight mod-
ifications. HEK293FT cells were transfected with truncated or mutated
tau using Lipofectamine 2000 (Invitrogen). Viruses were harvested in
Neurobasal medium 48 h after transfection. Neurons were incubated
with viral particles for72 h in a hypoxic incubator, before replacing the
growth media or fixing. The optimal transduction efficiency was deter-
mined by using an mCherry reporter lentivirus and through immuno-
fluorescent labeling with an AT8 antibody, which specifically recognized
Table 2. Information on the primary antibodies used in the studya
Antibody Dilution Manufacturer Catalog no.
Anti-TERT IF, 1:100; WB, 1:500 Abcam ab32020
Anti-TERT IF, 1:200 Rockland 600-401-252S
Anti-AT8 (PHF-tau (Ser202/Thr205) IF, 1:1000 Thermo MN1020
Anti-MTCO1 IF, 1:500; WB, 1:2000 Abcam ab14705
Anti-VDAC/porin IF, 1:200; WB, 1:1000 Abcam ab16816
Anti-GFAP (mouse) IF, 1:100 Abcam ab10062
Anti-CD68 (clone PG-M1) IF, 1:100 Dako NA
Anti-H2AX IF, 1:250 Cell signaling #9718
Anti-III-tubulin IF, 1:1000; WB, 1:1000 Abcam ab18207
Anti-GFAP (rabbit) IF, 1:1000 Dako NA
Anti-4 hydroxynonenal IF, 1:500 Abcam ab46545
Anti-calnexin IF, 1:100 Sigma C7617
Anti-AIF WB, 1:1000 Abcam ab32516
Anti-TOMM20 WB, 1:1000 Abcam ab56783
Anti-MnSOD WB, 1:1000 Millipore 06-984
Anti-NDUFA9 WB, 1:1000 Abcam ab14713
aIF,Immunofluorescence; WB, Western blotting; NA, not applicable.
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transduced neurons (see Fig. 7A, left images). Untransduced neurons
were not labeled with the AT8 antibody (see Fig. 7A, right images).
Immunofluorescence: cell cultures. Astrocytes or neurons grown on 19
mm glass coverslips (VWR) were fixed at 12 DIV and between 11 and 18
DIV, respectively, using 4% PFA for 10 min. They were subsequently
blocked and permeabilized in PBS containing 1% NGS and 0.2% Triton
X-100 for 30 min. Coverslips were incubated with primary antibodies
(Table 2) in PBS containing 1% NGS overnight at 4°C. AlexaFluor sec-
ondary antibodies (1:1000; Invitrogen) were added in PBS/NGS for 60
min.DAPIwas applied for 10min, and the coverslipsweremounted onto
microscope slides usingVectashield. Images were acquired using fluores-
cence microscopy or confocal microscopy. To measure colocalization,
images were deconvolved using the 3DHuygens Deconvolution & Anal-
ysis Software (Scientific Volume Imaging), and Pearson’s correlation
coefficients were calculated. Statistical analysis was performedusing one-
way ANOVA with Tukey’s post hoc test.
Measurement of superoxide in cultured neurons. Superoxide was mea-
sured in neurons on 96-well plates, after treatment with hydrogen per-
oxide (75 M, 1 U/ml glucose oxidase; 1 h). Neurons were incubated in
serum-free medium containing dihydroethidium (DHE; 1.25 M, 30
min at 37°C) using Hoechst 33342 (1 g/ml) to normalize for cell num-
ber (both Invitrogen). Subsequently, themediumwas changed andplates
read in a microplate reader (FLUOstar Omega, BMG Labtech) at wave-
lengths of 355/460 nm (Hoechst) and 544/590 nm (DHE). Background
fluorescence was subtracted from both measurements and the values
expressed as a ratio of DHE/Hoechst.
Measurement of mitochondrial superoxide and lipid peroxidation in cul-
tured neurons. Following transduction with truncated and mutated tau,
mitochondrial superoxide was measured using the MitoSOX probe (In-
vitrogen). Neurons were incubated with MitoSOX (5 M, 15 min at
37°C) in Neurobasal medium before fixation with 4% PFA and immu-
nolabeling with anti-AT8 antibody and counterstaining with DAPI. Mi-
toSOX fluorescence was imaged by confocal microscopy at wavelengths
of 540/560 nm. For measurement of lipid peroxidation, neurons were
immunolabeled with an anti-4-HNE antibody, alongside anti-AT8 anti-
body and nuclear counterstain. For fluorescent measurements, individ-
ual neurons were selected using the AT8 channel and imaged through
z-stacks. The soma was defined as the area immediately surrounding the
nucleus. The microtubules of dendrites were labeled with AT8. Apical
dendrites were identified as the thickest primary processes extending
from the apex of the soma, basal dendrites the thinner primary, and
secondary processes opposing the apical dendrite. Multiple line profiles
were taken for each subcellular region, and the average pixel intensitywas
calculated.
Results
TERT expression in human hippocampus, and in cultured
neurons and glial cells
To date, the expression of TERT protein in adult human brain
has not been described. To examine which cells within human
brain tissue express TERT protein, we performed immunolabel-
ing of hTERT protein in hippocampal sections from aged indi-
viduals. The anti-TERT monoclonal antibody used in this study
(ab32020, Abcam) has been validated for specificity by us (Fig.
1B, bottom, D) and by others (Eitan et al., 2012b; Xi et al., 2013;
Zaug et al., 2013), and a single amino-acid substitution in the
C-terminal epitope of hTERT has been shown to abolish the
signal (Zaug et al., 2013). Immunostaining revealed TERT pro-
tein in hippocampal neurons (Fig. 1A, top two rows). TERT flu-
orescence was found in the cytoplasm throughout the soma and
dendrites. However, there was not a considerable amount of nu-
clear staining. TERT staining in human neurons was also verified
using an hTERT antibody from Rockland (Fig. 1C). When sec-
tions were costainedwith TERT andGFAP,GFAP-positive astro-
cytes did not express TERT (Fig. 1A, bottom row). However,
TERT was expressed in activated microglia labeled with CD68
(Fig. 1A, third row).
We also examinedTERT expression in vitro in culturedmouse
brain cells. We derived neuronal and glial cultures from embry-
onicmouse cortex and identifiedwhich of the cell types expressed
TERT protein in vitro. In primary neuronal cultures double im-
munolabeled with III-tubulin and TERT, we observed TERT
protein in the cytoplasm of the soma and dendrites (Fig. 1B, top
row). In mixed glial cultures (14 DIV), we found an intense la-
beling of activatedmicroglia, which were identified using a CD68
antibody (Fig. 1B, second row), whereas astrocytes labeled with
GFAP displayed a small amount of fluorescence in the cytoplasm
(Fig. 1B, third row). The latter observation is most likely due to
the fact that cultured astrocytes express telomerase initially and
that it is quickly downregulated on reaching confluence. Using a
TRAP ELISA, we also measured telomerase activity in neurons at
3–14 DIV. We found a strong reduction in telomerase activity of
neurons11 d in culture (Fig. 1E) corresponding to earlier ob-
servations (Fu et al., 2002a).
It has been shown that there is a reduction in expression of
TERT protein in brain in a model of neurodegenerative disease
(amyotrophic lateral sclerosis [ALS]), and in Purkinje neurons
during normal aging in mice (Eitan et al., 2012a, 2012b). How-
ever, it is currently unknown whether this also occurs during
human aging and in neurodegenerative disease. Therefore, we
measured TERT protein expression in the hippocampus during
progression of AD pathology as reflected by Braak stages, using
three independent methods. Because TERT is known to have
protective noncanonical functions in vitro (Fu et al., 2000;
Ahmed et al., 2008; Haendeler et al., 2009; Sharma et al., 2012;
Saretzki, 2014) and in vivo (Kang et al., 2004; Lee et al., 2008;
Eitan et al., 2012b), we hypothesized that a decrease in TERT
protein may play a role in neuronal susceptibility to tau pathol-
ogy. We chose to investigate the relationship between TERT and
hyperphosphorylated tau specifically because tau, like TERT, is
predominantly intracellular where it occurs in cellular somata in
the form of neurofibrillary tangles and in neuronal processes as
neuropil threads (Alonso et al., 1996; Duyckaerts et al., 2009).
Moreover, tau is the more prevalent AD pathology in the hip-
pocampus. Taumay be also be present extracellularly in the form
of so-called “ghost tangles,” where the tangle-bearing neurons
have died off and only the tangles remain (Cras et al., 1995). In
addition, TERT and tau have both been shown to interact with
mitochondrial proteins, having opposite effects on the activity of
complex I of the electron transport chain (Haendeler et al., 2009;
Rhein et al., 2009).
We performed Western blotting detecting TERT in protein
lysates from hippocampal tissue of healthy age-matched control
cases (Braak Stage 0), from cases with low Braak stages (I-III),
and fromAD cases (i.e., Braak Stage VI).We chose to include low
Braak stage cases to examine whether there was a relationship
between the amount of hippocampal tau pathology and the levels
of TERT expression. The anti-TERT antibody detected clear
bands of the correct size. Bands were quantified and normalized
to neuronal III-tubulin and revealed that TERT expression did
not differ between controls and cases with Braak Stage I-VI (Fig.
2A). To corroborate our findings, a sandwich ELISA detecting
TERT protein was used to measure TERT expression in controls
and from each of these Braak stages: I/II, III, and VI (Fig. 2B).
Results from these experimentswere in agreementwith theWest-
ern blotting data indicating no change in total TERT expression
between controls and the different Braak stages.
Because lysates used in Western blots and TERT ELISA con-
tained total protein from all hippocampal cell types, we used
immunofluorescence to enable a more sensitive measurement of
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neuronal TERT expression. Using immunofluorescent staining,
we labeled hippocampal sections with TERT and NeuroTrace, a
neuron-specific fluorescent Nissl stain (Fig. 2D), and TERT ex-
pression was quantified in hippocampal sectors CA1, CA2, CA3,
CA4, and DG (granule cell layer). However, these measurements
also indicated that TERT expression in individual neurons is un-
changed between controls and Braak Stage I-VI cases, regardless
of the hippocampal region (Fig. 2C).
Together, these data suggest that there does not seem to be a
change in TERT protein levels in hippocampal neurons in the
early and intermediate Braak stages of tau pathology or in AD.
TERT colocalizes with mitochondria in advanced AD
pathology
It has been shown, that under conditions of oxidative stress,
TERT shuttles to the mitochondria, where it reduces ROS pro-
duction, increases mitochondrial membrane potential, and im-
proves respiratory chain function (Ahmed et al., 2008; Haendeler
et al., 2009; Singhapol et al., 2013). Because we saw no differences
in TERT protein levels in hippocampus at any Braak stage, we
hypothesized that TERTmay undergo a shift in subcellular local-
ization to the mitochondria in neurons upon AD pathology. To
investigate this, double immunofluorescent labeling of MTCO1
(COX1 protein from complex IV of the electron transport chain)
and TERT was performed (Fig. 3A–C), and colocalization deter-
mined between the two proteins. Pearson’s correlation analysis
showed a significant increase in the proportion of colocalization
between TERT andmitochondria in surviving hippocampal neu-
rons in CA1 (128 11.9%, p 0.021), CA2 (107 10.3%, p
0.002), and CA3 (74 9.9%, p 0.029) in AD (i.e., Braak Stage
VI) compared with controls (Fig. 3D). However, we found no
significant differences in the CA4 or DG regions, or between
Figure 1. Expression of TERT in human hippocampus and in cultured neurons and glia. A, Images showing immunohistochemical and immunofluorescent labeling of TERT in human hippocam-
pus. Top, TERT (brown) and hematoxylin (blue) labeled neurons in the CA1 and CA3 regions of the hippocampus. Right, Immunofluorescence image shows secondary antibody only control (green).
Arrows indicate neuronal nuclei. *Autofluorescence of a blood vessel. Second panel, TERT (green) is detected in the cytoplasmof neurons,which are identified using the neuronalmarker NeuroTrace
(red) and nuclear counterstain (DAPI; blue). Third panel, TERT (red) is expressed bymicroglial cells, as determined using antibodies against themicroglial marker, CD68 (green). Bottom, TERT (red)
specific stainingwasabsent inastrocytes, asdeterminedbydouble-labelingwithastrocytemarker, GFAP (green).B, Images showing immunofluorescent labelingof TERT (red) in culturedembryonic
mouse neurons and glia. The cell-specificmarkersIII-tubulin, CD68, andGFAP identify neurons,microglia, and astrocytes, respectively (green). Top, Neurons express TERT protein in the cytoplasm
of the somaanddendrites, but not in thenucleus. Secondpanel, Activatedmicroglia showhigh expression of TERTprotein in the cytoplasm. Third panel, Astrocytes in culture donot show fluorescent
staining of TERT protein. Bottom, Neurons derived from TERT/mice do not label with the anti-TERT antibody. C, An additional antibody recognizing TERT (Rockland) also labels the cytoplasm of
humanneurons.D, TERTantibody (Abcam) specificity is demonstrated inMRC5andMRC5-hTERToverexpressing fibroblasts. Top,MRC5 fibroblasts showanabsenceof TERT staining.Bottom, Intense
labeling of TERT (red) in the nucleus ofMRC5-hTERT overexpressing fibroblasts.E, Telomerase activity is downregulated in embryonicmouse neurons in culture. Data aremean SEM. Scale bars, 50M.
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controls (Braak Stage 0) and cases with intermediate Braak stages
(I-III). The lack of an increase in colocalization in the CA4 or DG
regions at Braak Stage VI could be due to these regions being less
severely affected by tau pathology than the CA1, CA2, and CA3
regions (Lace et al., 2009).
To exclude that the increased TERT colocalization with mito-
chondria in AD cases is due to advanced Braak stages having a
higher mitochondrial content, the latter was analyzed. Using
Western blotting, we measured the expression of two mitochon-
drial proteins in lysates from AD cases (i.e., Braak Stage VI) and
controls. However, there were no significant differences in levels
of VDAC/porin or MTCO1 protein (Fig. 4A). To confirm this
result, immunolabeling of hippocampal sections with MTCO1
was performed, and fluorescence measured in neurons of the
CA1, CA2, CA3, and CA4. There were no significant differences
in MTCO1 fluorescence intensity between controls and Braak
Stage VI AD cases (Fig. 4B). This is in agreement with previous
findings (Wang et al., 2009). Nevertheless, it is possible that ac-
tivity of the respiratory complexes may be altered in neurons of
the AD brain (Mutisya et al., 1994; Maurer et al., 2000).
TERT protein is present in mouse liver mitochondrial
subfractions
To demonstrate localization of TERT within mitochondria, we
isolated pure mitochondria from wild-type mouse liver and sub-
fractionated them giving rise to mitoplast, proteinase K-shaved
mitoplast, and inner membrane fractions. Western blotting re-
vealed that TERT was enriched in mitochondria compared with
whole liver lysate (Fig. 4C). In addition, bands specific to TERT
were observed in the mitoplast, proteinase K-shaved mitoplast,
and inner membrane fractions.
Mutual exclusion of TERT and pathological tau in AD
Considering the known protective functions of TERT in other
cell systems, we hypothesized that TERT-expressing neurons
could be more resistant to tau pathology. To determine whether
TERT and pathological tau are present together in the same neu-
rons, double immunofluorescent labeling was performed with
antibodies recognizing TERT and hyperphosphorylated tau. Sec-
tions from cases with Braak Stage 0 and with Braak Stages III-VI
were analyzed for TERT and AT8. As expected, in cases at Braak
Stage 0, TERT staining was apparent in the neuronal cytoplasm,
and no AT8 immunoreactivity was seen (Fig. 5, top row). In the
sections of Braak Stages III-VI, AT8 immunoreactivity was found
both as neuropil threads in neuronal cell processes and neurofibril-
lary tangles in neuronal somata. Interestingly, we did not find any
overlapping of the TERT and AT8 signals, suggesting that TERT
expression and the presence of tau pathology aremutually exclusive
in neurons of the hippocampus (Fig. 5, bottom two rows).
Neurons lacking TERT have increased susceptibility to
oxidative stress
Hydrogen peroxide increases mitochondrial superoxide in
TERT / neurons
It has been shownpreviously that knocking downTERT in cultured
neurons resulted in increased susceptibility to oxidative stress and
Figure 2. Expression of TERT protein in the hippocampus at different Braak stages.A, Appropriately sized bands represent hTERT protein (127 kDa) andIII-tubulin (55 kDa) as a loading control.
Graph represents densitometric analysis of relative banddensities for hTERTprotein. Data aremean SEM for 3 cases per group, analyzedusingone-wayANOVA.B, Graph represents levels of hTERT
protein determined using a TERT ELISA. Data are mean SEM from 6 cases per group, analyzed using one-way ANOVA. C, Hippocampal sections from age-matched controls, and from three AD
groups, Braak I-II, III, and VI, were labeled with anti-TERT antibody (green) and a fluorescent Nissl stain (NeuroTrace; red). Graph represents quantification of TERT immunofluorescence in neurons
from five different areas of the hippocampus: CA1, CA2, CA3, CA4, and DG. Data are mean SEM from 3 cases per group, analyzed using one-way ANOVA. D, Two representative fluorescence
microscopy images show TERT and NeuroTrace-labeled neurons in the CA1 of a control donor and a Braak Stage VI donor. Scale bars, 50M.
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apoptosis (Fu et al., 2000; Zhu et al., 2000; Lu et al., 2001). These
findings suggest that TERT protein has protective functions in neu-
rons. Thus, we hypothesized that neurons cultured from TERT/
mice would be less resistant to oxidative stress than wild-type
neurons. Neurons from both genotypes were exposed to hydrogen
peroxide, and mitochondrial superoxide production was measured
using DHE. As expected, H2O2 treatment led to a small but signifi-
cant increase in DHE fluorescence of 66 3.7% in TERT/ neu-
rons compared with untreated controls (Fig. 6A; p 0.035). There
was no difference in the levels of superoxide in wild-type neurons
exposed toH2O2 comparedwith theuntreated controls. In addition,
we did not find any difference in the DHE levels between the two
genotypes without oxidative stress. These data support previous
findings that TERT protects cells (Ahmed et al., 2008; Haendeler et
Figure 3. TERT protein colocalizes with mitochondria under AD pathology. Representative series of sequential confocal images showing immunofluorescent labeling of TERT (green) and
mitochondria (MTCO1, red) in CA2 hippocampal neurons from (A) a control and (B) a Braak Stage VI case (DAPI, blue). Images shown are from the middle section of Z-stacks containing a total of
20–24 planes. C, Maximum intensity projection images of TERT and mitochondria derived from Z-stack series covering the total section depth. D, Bar graphs represent Pearson’s coefficients
indicating the degree of colocalization between TERT andmitochondria in CA1, CA2, CA3, CA4, and DG regions of the hippocampus. Colocalizationwas increased in the CA1, CA2, and CA3 regions of
AD (Braak VI) cases compared with the control group. Data are mean SEM from 3 cases per group. *p	 0.05 (one-way ANOVA with Tukey’s post hoc test). **p	 0.01 (one-way ANOVA with
Tukey’s post hoc test). ns, Not significant. Scale bars, 50M; maximum intensity projection image, 20M.
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al., 2009), and suggest that a loss of TERTmay result in an increased
susceptibility to oxidative damage.
Oxidative stress induces mitochondrial localization of TERT in
cultured neurons
Under conditions of oxidative stress, TERT has previously been
shown to shuttle to mitochondria (Santos et al., 2004; Ahmed et
al., 2008; Haendeler et al., 2009; Singhapol et al., 2013) and de-
crease ROS production and mitochondrial DNA damage, in-
crease mitochondrial membrane potential (Ahmed et al., 2008),
and improve Ca2 uptake in different cell types, including neu-
rons (Kang et al., 2004). To investigate whether TERT shuttles to
mitochondria in our cultured neurons following oxidative stress,
wild-type neurons were exposed to hydrogen peroxide and colo-
calization analysis was performed using anti-TERT and anti-
MTCO1 antibodies (Fig. 6C). In neurons exposed to hydrogen
peroxide, TERT colocalization with mitochondria was increased
compared with untreated control (64  4.8%, p  0.017) (Fig.
6B). A smaller amount of TERT protein was found to be localized
at the nucleus, and this was unchanged following exposure to
hydrogen peroxide (Fig. 5B). To check whether TERT is localized
at othermajor cellular compartments, immunofluorescent stain-
ing of endoplasmic reticulum (ER) was performed using an anti-
calnexin antibody. There was no substantial colocalization
between TERT and the ER (Fig. 6D).
We observed a mutual exclusion of pathological tau and
TERT in human hippocampal neurons and hypothesized that
this might be due to a downregulation of TERT expression fol-
lowing tau pathology. However, in cultured neurons transduced
with empty vector, truncated tau, or mutated tau, we did not
observe differences in levels of TERT protein (Fig. 6E,G). In
addition, mitochondrial content was unchanged in tau trans-
duced neurons (Fig. 6F).
TERT protects against tau pathology in vitro
Pathological tau increases mitochondrial superoxide in
TERT/ neurons
To investigate whether TERT protein reduces oxidative damage
induced by pathological tau, neurons from wild-type and
TERT/mice were cultured and transduced with lentiviral vec-
tors containing two pathological tau variants: truncated tau
(151–391aa) and mutated (P301L) tau. Following transduction
with either truncated tau or P310L tau, the AT8 antibody
specifically labeled the dendrites of neurons, with less intense
staining of the somata (Fig. 7A, left image). Neuronal trans-
duction was optimized, achieving high efficiency as shown by
the mCherry reporter plasmid (Fig. 6A, second image). In
transduced neurons from wild-type and TERT/ mice, Mi-
toSOX staining was measured in the soma, apical, and basal
dendrites (Fig. 6B,C). The MitoSOX signal was increased by
63  9.6% in the basal dendrites of TERT/ neurons trans-
duced withmutated tau compared with wild-type (Fig. 7E; p
0.013), although no significant differences were seen in other
cell areas or in neurons transduced with truncated tau (Fig.
6D). There were no significant differences in MitoSOX inten-
sity between neurons from the two genotypes when trans-
duced with truncated tau.
Figure 4. Levels ofmitochondrial proteins are unchanged in AD.A,Western blots formitochondrial proteinswere performedwith lysates from controls and fromAD cases (Braak Stage VI). There
were no significant differences in levels of VDAC/porin or MTCO1 protein (n 5 or 6, p 0.05). Data are mean SEM and were analyzed using a two-sample t test. B, Histogram showing
quantification ofMTCO1-immunolabeled hippocampal sections. There are no significant differences in fluorescence intensity between control and AD cases (n 3, p 0.05). Scale bars, 50M. C,
Mouse liver mitochondria were isolated, then subfractionated into mitoplast, proteinase K-shaved mitoplast, and inner membrane fractions. Western blots show appropriately sized bands
representingmTERT (127kDa) and themitochondrialmarker proteins: AIF (67kDa;matrix/innermitochondrialmembrane), TOM20 (20kDa; outermitochondrialmembrane/intermembrane space),
MnSOD (25kDa;matrix), andNDUFA9 (36kDa; innermitochondrialmembrane). TERTprotein expression is found in all fractions.H, Liver homogenate;M,puremitochondria;MP,mitoplast; IM, inner
mitochondrial membrane.
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Pathological tau increases lipid peroxidation in TERT/ neurons
Increased production of mitochondrial superoxide causes oxida-
tion of cellular structures, including lipid membranes (Sayre et
al., 1997), proteins (Perluigi et al., 2009), and mitochondrial and
nuclearDNA (Lovell andMarkesbery, 2007).Hence, we expected
that TERT/ neurons would display higher levels of lipid per-
oxidation in response to pathological tau than wild-type. 4-HNE
staining was increased by 76  17.7% in the soma of TERT/
neurons transduced with mutated tau compared with wild-type
(Fig. 8D; p  0.029), although no changes were found in the
dendrites. There were no significant differences between geno-
types when transduced with truncated tau (Fig. 8C). This result is
in accordance with the increased oxidative stress seen in
TERT/ neurons after transduction withmutated, but not with
truncated tau.
Discussion
TERT expression in the human brain
In rodent brain, telomerase activity is high during embryonic
development but quickly downregulated postnatally (Klapper et
al., 2001). However, expression of TERT has been described to
persist into adulthood inmouse and rat (Klapper et al., 2001; Lee
et al., 2010; Eitan et al., 2012b), and in neurons specifically (Eitan
et al., 2012a). However, little is known about TERT expression in
adult human brain. We demonstrated that TERT protein is ex-
pressed in the cytoplasm of neurons of the CA1, CA2, CA3, CA4,
and DG regions of the adult hippocampus. We found that acti-
vated microglial cells express TERT protein, corresponding to
previous findings in mice (Fu et al., 2002b; Flanary and Streit,
2005). Astrocytes did not express TERT, which is also in accor-
dance with previous findings in developing mouse cortex and
hippocampus (Fu et al., 2000).
In primary neurons, we found that telomerase activity was lost
11 d in culture (Fig. 1E), whereas TERT protein expression
persisted (Fig. 1B) corresponding to previous observations (Fu et
al., 2002a). We expected a reduction in neuronal TERT expres-
sion with progression through increasing Braak stages to clinical
AD, leading to susceptibility to pathology, similar to findings in a
mousemodel of ALS (Eitan et al., 2012b). However, we found no
changes in TERT protein expression in hippocampus of early
Braak stage cases (I-III) or in AD cases compared with healthy
age-matched controls using three independent methods.
TERT andmitochondria in AD brain
In dividing cells, TERT is known to be exported from the nucleus
and to enter mitochondria upon cellular stress (Santos et al.,
Figure 5. TERT and pathological taumutually exclude each other. Sections fromBraak Stage 0 and Braak Stages III-VIwere labeled for TERT (red) and pathological tau (AT8; green). In the control
cases, TERT immunoreactivity is present; however, AT8 staining is absent. In cases with higher Braak stages, AT8 staining is seen as NTs in dendrites and NFTs in the soma. Tangle-bearing neurons
are not immunoreactive for TERT, and TERT-expressing neurons do not contain AT8. Scale bars, 50M.
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Figure 6. Neurons lacking TERT have an increased susceptibility to oxidative stress. A, Cultured neurons were exposed to hydrogen peroxide, and the production of superoxide was measured
using DHE. DHE levels were increased in TERT/ neurons exposed to hydrogen peroxide compared with control. *p	 0.05 (two-sample t test). Data are mean SEM from three independent
experiments. ns, Not significant. B, Oxidative stress increases mitochondrial localization of TERT in cultured neurons. *p 	 0.05 (two-sample t test). Wild-type (Figure legend continues.)
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2004; Ahmed et al., 2008; Haendeler et al., 2009). In neurons of
the human hippocampus, we detected themajority of TERT out-
side the nucleus, which could be due to them being postmitotic
and without need for telomeremaintenance. Iannilli et al. (2013)
showed that TERT levels increased in the cytoplasm and de-
creased in the nucleus in cultured hippocampal rat neurons with
time in vitro. The same authors demonstrated that TERT forms a
complex with p15 mRNA preventing its translation in the cyto-
plasmof neurons.Uponoxidative stress, this complex is resolved,
p15 translated, and TERT is free move to the mitochondria (Ian-
nilli et al., 2013). Thus, we suggest that neuronal TERT might be
localized preferentially in the cytoplasm and move to mitochon-
dria under conditions of increased oxidative stress.
We found a greater proportion of TERT protein colocalized
withmitochondria in hippocampal neurons of the CA1, CA2 and
CA3 at Braak Stage VI, compared with the same region in con-
trols. Mammalian TERT protein contains amitochondrial leader
sequence, which allows interaction with the translocase com-
plexes and entry into the mitochondrial matrix (Santos et al.,
2004; Haendeler et al., 2009; Sharma et al., 2012). Within the
mitochondria, TERThas been shown to reduce cellular ROS pro-
duction and improvemitochondrial function as well as to reduce
apoptosis after cellular stress (Ahmed et al., 2008; Haendeler et
al., 2009; Singhapol et al., 2013). Our results suggest that, under
the cellular stress resulting from AD pathology, TERT moves to
mitochondria where it may improve respiratory chain function
and to decrease ROS levels. In a transgenic mouse model of AD,
amyloid  (A) was shown to cause complex IV deficits, whereas
tau pathology specifically affected complex I (Rhein et al., 2009).
Because TERT has been shown to improve complex I activity
(Haendeler et al., 2009), one could speculate that there might be
a direct functional interaction of both proteins at this mitochon-
drial site. When we investigated TERT protein expression in dif-
ferent mitochondrial fractions from mouse liver, we found
enrichment of TERT in themitochondria. In addition, TERTwas
found in mitochondrial subfractions up to and including at the
inner membrane. These data correspond to previous findings by
others that TERT is imported into the organelles (Haendeler et
al., 2009; Sharma et al., 2012).
TERT and tau in AD brain
Two of the features commonly observed in the AD brain are
compromised energy production (Atamna and Frey, 2007) and
formation of neurofibrillary tangles, as a result of hyperphospho-
rylation of tau (Grundke-Iqbal et al., 1986). The two could be
causally linked because an impairment of mitochondrial func-
tion leads to increased ROS production, which may promote
hyperphosphorylation of tau (Melov et al., 2007). In turn, forma-
tion of hyperphosphorylated tau could also impair retrograde
mitochondrial movement along microtubules (Ebneth et al.,
1998) and so lead to ATP depletion in the axons and dendrites,
resulting in synaptic dysfunction (Mattson and Liu, 2002). At
present, it remains unclear which of these two processes, oxida-
tive stress or hyperphosphorylation of tau, occurs first.
In the hippocampus of patients with Braak Stage III and VI
pathology, we observed a mutual exclusion of TERT and both
neuropil threads and neurofibrillary tangles. In contrast, control
brains (Braak Stage 0) displayed only TERT-positive neurons.
This suggests that either TERT expressing neurons are prevented
from developing tau pathology or that TERT protein is lost fol-
lowing formation of NTs and NFTs. In cultured mouse neurons,
we found that TERT expression was unaffected by transduction
with truncated andmutated tau. However, it cannot be excluded
that pathological tau causes a downregulation of TERT protein
when expressed over a longer time period. Although we did not
find obvious changes in TERT protein levels in AD brains, there
was a subcellular redistribution of TERT to more mitochondrial
localization in Braak Stage VI cases.
TERT in an in vitromodel of tau pathology
Comparing neurons from wild-type and TERT/ mice, we
found that the absence of TERT protein resulted in increased
mitochondrial superoxide production following exposure to hy-
drogen peroxide. We sought to analyze whether TERT protein
also protected against pathological tau in cultured neurons. Mu-
tations in the tau gene, such as P301L in frontotemporal demen-
tia, cause neurodegeneration through hyperphosphorylation of
tau, which translocates to somatodendritic areas and forms ag-
gregates as NFT (Hutton et al., 1998; Varani et al., 1999; David et
al., 2005; Go¨tz and Ittner, 2008). Truncated tau species have also
been shown to associate with NFTs in AD and contribute to
neuronal dysfunction (Mena et al., 1996; Cente et al., 2006;
Zilkova et al., 2011). Both forms can be hyperphosphorylated and
form aggregates in vitro and in animal models of AD (Go¨tz et al.,
2001; Cente et al., 2006; Zilka et al., 2006; Bi et al., 2011; Zilkova
et al., 2011; Giustiniani et al., 2014). In one recent study, injection
of a lentivirus containing P301L tau into the brains of mice re-
sulted in tau phosphorylation at sites important for paired helical
filament formation, including Thr 181 (AT270) and Ser 262,
whereas wild-type tau had no such effect (Biernat et al., 1993;
Khandelwal et al., 2012). In sporadic AD, it is wild-type tau that is
associatedwith development of pathology. There are a number of
mouse models available which use wild-type tau to mimic spo-
radic AD (Go¨tz et al., 1995; Brion et al., 1999; Probst et al., 2000;
Andorfer et al., 2005; Jaworski et al., 2009; Caillierez et al., 2013;
Dujardin et al., 2014). However, we chose not to use the full-
length tau because generally its cytotoxic effects in vitro are less
pronounced than the mutated or truncated tau forms (Abraha et
al., 2000; Fath et al., 2002; Khlistunova et al., 2006).
Therefore, we tested the protective effects of TERT against
truncated tau and P301L mutant tau. Importantly, we found in-
creasedmitochondrial superoxide generation and lipid peroxida-
tion in TERT/ neurons transduced with mutated P301L tau.
Increased mitochondrial superoxide was detected in the den-
drites of TERT/ neurons. Normally, dendrites of cultured
neurons are devoid of tau. We suggest that tau hyperphosphory-
lation in the dendrites results in increased MitoSOX due to dys-
functional trafficking of mitochondria along these processes.
Lipid peroxidation was increased in the neuronal somata of
TERT/ neurons transduced with mutated P301L tau, com-
paredwithwild-type. This is likely due to the cell body containing
4
(Figure legend continued.) neurons were exposed to hydrogen peroxide and analyzed for
colocalization between TERT andMTCO1 or TERT and the nuclear stain, DAPI. Data aremean
SEM from three independent experiments. C, Representative images showing TERT andMTCO1
immunofluorescent labeling of neurons in culture. White arrowheads indicate regions of colo-
calization.White arrows indicate absence of colocalization. Inset, 2magnification.D, Immu-
nofluorescent labeling of cultured neuronswith calnexin (red) and TERT (green) shows that the
majority of TERT does not colocalize with endoplasmic reticulum. Scale bars, 50M. E, Repre-
sentative Western blot showing specific bands for TERT and the mitochondrial protein porin in
cultured neurons, transducedwith vector control, truncated tau, or mutated tau. F, Quantifica-
tion of Western blot shows no differences in level of TERT protein between groups (n 4). G,
Quantification of Western blot shows no differences in the level of porin protein expression
between groups. Data are mean SEM from four independent experiments, analyzed using
one-way ANOVA.
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Figure 7. Pathological tau increases mitochondrial superoxide in TERT/ neurons. A, A high proportion of P301L-transduced neurons are labeled with AT8 (green; left). The optimal
transduction efficiency was determined using a fluorescent reporter lentivirus. Neurons transduced with lentivirus-containing 53BP1-mCherry were -irradiated to induce DNA damage. The
majority of cells were transduced, as indicated by the nuclei containing 53BP1 foci (red; second panel). Untransduced neurons do not label with anti-AT8 antibody.B, C, Neurons fromwild-type and
TERT/micewere transducedwith either truncated tau (B) ormutated tau (C). Double-labelingwithMitoSOX (red) and anti-AT8 (green)was conducted, and levels of superoxideweremeasured
in three cell areas: the soma, apical dendrites, and basal dendrites.D, There were no differences inMitoSOX fluorescence betweenwild-type and TERT/ neurons transducedwith truncated tau.
E,MitoSOX fluorescencewas increased in thedendrites of TERT/neurons transducedwithmutated tau. *p	0.05 (one-wayANOVAwith Tukey’spost hoc test). Data aremeanSEM fromthree
independent experiments.
1670 • J. Neurosci., January 28, 2015 • 35(4):1659–1674 Spilsbury et al. • Telomerase Protein TERT in Alzheimer’s Disease
the highest concentration of lipid membranes. Interestingly, lev-
els of superoxide and lipid peroxidation were not significantly
different between wild-type and TERT/ neurons transduced
with truncated tau. Expression of truncated tau has been de-
scribed to generate increased oxidative stress previously over a
longer time course (Cente et al., 2006). Although we found tau
hyperphosphorylation, the truncated tau protein, might need
more time to affect ROS generation. These data demonstrate that
there might be differences in the kinetics or mechanism of ROS
induction between the two tau forms.
Together, our results suggest that the telomerase protein
TERT seems to be a protective factor in the brain and may offer
neuronal resistance against pathological tau by reducing pro-
duction of oxidative species and improving mitochondrial
function. New telomerase activating compounds have been
described, one of which was shown to be effective in reducing
disease symptoms and extending lifespan in a mouse model of
ALS (Eitan et al., 2012b). These telomerase activators could
form a basis for novel preventative treatments for neurode-
generative diseases.
Figure 8. Pathological tau increases lipid peroxidation in TERT/ neurons. Neurons from wild-type and TERT/ mice were transduced with either truncated (A) or mutated (B) tau.
Double-labelingwith 4-HNE (red) and AT8 (green)was performed, and levels of lipid peroxidationweremeasured in the soma, apical dendrites, and basal dendrites. C, Therewere no differences in
4-HNE levels betweenwild-type and TERT/neurons transducedwith truncated tau.D, 4-HNEwas increased in the somaof TERT/neurons transducedwithmutated tau. *p	0.05 (one-way
ANOVA with Tukey’s post hoc test). Data are mean SEM from three independent experiments. Scale bars, 50M.
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Notes
Supplemental material for this article is available at http://dev-research.
ncl.ac.uk/saretzki/. This material has not been peer reviewed.
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